Next Article in Journal
Multifunctional Composite Microcapsules for Oral Delivery of Insulin
Previous Article in Journal
Simultaneous Determination and Pharmacokinetic Study of Six Components in Rat Plasma by HPLC-MS/MS after Oral Administration of Acanthopanax sessiliflorus Fruit Extract
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(1), 57; doi:10.3390/ijms18010057

Immuno-PET for Clinical Theranostic Approaches

1
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, 8 quai Moncousu, 44007 Nantes, France
2
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France
3
Groupement d’Intérêt Public Arronax, 1, rue Aronnax, CS 10112, 44817 Saint-Herblain, France
4
Department of Nuclear Medicine, Institut de Cancérologie de l’Ouest (ICO)-René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France
*
Author to whom correspondence should be addressed.
Academic Editor: Vera Sau-Fong Chan
Received: 3 November 2016 / Revised: 16 December 2016 / Accepted: 23 December 2016 / Published: 28 December 2016
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
View Full-Text   |   Download PDF [1032 KB, uploaded 28 December 2016]   |  

Abstract

Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals. View Full-Text
Keywords: immuno-PET; molecular imaging; antibody immuno-PET; molecular imaging; antibody
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Bailly, C.; Cléry, P.-F.; Faivre-Chauvet, A.; Bourgeois, M.; Guérard, F.; Haddad, F.; Barbet, J.; Chérel, M.; Kraeber-Bodéré, F.; Carlier, T.; Bodet-Milin, C. Immuno-PET for Clinical Theranostic Approaches. Int. J. Mol. Sci. 2017, 18, 57.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top